166 related articles for article (PubMed ID: 15841327)
1. Suppression of rat breast cancer metastasis and reduction of primary tumour growth by the small synthetic urokinase inhibitor WX-UK1.
Setyono-Han B; Stürzebecher J; Schmalix WA; Muehlenweg B; Sieuwerts AM; Timmermans M; Magdolen V; Schmitt M; Klijn JG; Foekens JA
Thromb Haemost; 2005 Apr; 93(4):779-86. PubMed ID: 15841327
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of the invasion capacity of carcinoma cells by WX-UK1, a novel synthetic inhibitor of the urokinase-type plasminogen activator system.
Ertongur S; Lang S; Mack B; Wosikowski K; Muehlenweg B; Gires O
Int J Cancer; 2004 Jul; 110(6):815-24. PubMed ID: 15170662
[TBL] [Abstract][Full Text] [Related]
3. High-affinity urokinase-derived cyclic peptides inhibiting urokinase/urokinase receptor-interaction: effects on tumor growth and spread.
Sato S; Kopitz C; Schmalix WA; Muehlenweg B; Kessler H; Schmitt M; Krüger A; Magdolen V
FEBS Lett; 2002 Sep; 528(1-3):212-6. PubMed ID: 12297307
[TBL] [Abstract][Full Text] [Related]
4. Prevention of breast cancer growth, invasion, and metastasis by antiestrogen tamoxifen alone or in combination with urokinase inhibitor B-428.
Xing RH; Mazar A; Henkin J; Rabbani SA
Cancer Res; 1997 Aug; 57(16):3585-93. PubMed ID: 9270032
[TBL] [Abstract][Full Text] [Related]
5. Reduction of breast carcinoma tumor growth and lung colonization by overexpression of the soluble urokinase-type plasminogen activator receptor (CD87).
Krüger A; Soeltl R; Lutz V; Wilhelm OG; Magdolen V; Rojo EE; Hantzopoulos PA; Graeff H; Gänsbacher B; Schmitt M
Cancer Gene Ther; 2000 Feb; 7(2):292-9. PubMed ID: 10770639
[TBL] [Abstract][Full Text] [Related]
6. Calcitonin inhibits invasion of breast cancer cells: involvement of urokinase-type plasminogen activator (uPA) and uPA receptor.
Han B; Nakamura M; Zhou G; Ishii A; Nakamura A; Bai Y; Mori I; Kakudo K
Int J Oncol; 2006 Apr; 28(4):807-14. PubMed ID: 16525628
[TBL] [Abstract][Full Text] [Related]
7. Multimodal therapy for synergic inhibition of tumour cell invasion and tumour-induced angiogenesis.
Zengel P; Ramp D; Mack B; Zahler S; Berghaus A; Muehlenweg B; Gires O; Schmitz S
BMC Cancer; 2010 Mar; 10():92. PubMed ID: 20222943
[TBL] [Abstract][Full Text] [Related]
8. Interference with the urokinase plasminogen activator system: a promising therapy concept for solid tumours.
Muehlenweg B; Sperl S; Magdolen V; Schmitt M; Harbeck N
Expert Opin Biol Ther; 2001 Jul; 1(4):683-91. PubMed ID: 11727504
[TBL] [Abstract][Full Text] [Related]
9. Cyclo19,31[D-Cys19]-uPA19-31 is a potent competitive antagonist of the interaction of urokinase-type plasminogen activator with its receptor (CD87).
Magdolen V; Bürgle M; de Prada NA; Schmiedeberg N; Riemer C; Schroeck F; Kellermann J; Degitz K; Wilhelm OG; Schmitt M; Kessler H
Biol Chem; 2001 Aug; 382(8):1197-205. PubMed ID: 11592401
[TBL] [Abstract][Full Text] [Related]
10. Urokinase-type plasminogen activator and its receptor: new targets for anti-metastatic therapy?
Fazioli F; Blasi F
Trends Pharmacol Sci; 1994 Jan; 15(1):25-9. PubMed ID: 8140655
[TBL] [Abstract][Full Text] [Related]
11. Elevated urokinase-specific surface receptor expression is maintained through its interaction with urokinase plasminogen activator.
Mahanivong C; Yu J; Huang S
Mol Carcinog; 2007 Mar; 46(3):165-75. PubMed ID: 17186542
[TBL] [Abstract][Full Text] [Related]
12. Plasminogen activator inhibitor-1 as a measure of vascular remodelling in breast cancer.
Fox SB; Taylor M; Grøndahl-Hansen J; Kakolyris S; Gatter KC; Harris AL
J Pathol; 2001 Sep; 195(2):236-43. PubMed ID: 11592104
[TBL] [Abstract][Full Text] [Related]
13. Renal synthesis of urokinase type-plasminogen activator, its receptor, and plasminogen activator inhibitor-1 in diabetic nephropathy in rats: modulation by angiotensin-converting-enzyme inhibitor.
Kenichi M; Masanobu M; Takehiko K; Shoko T; Akira F; Katsushige A; Takashi H; Yoshiyuki O; Shigeru K
J Lab Clin Med; 2004 Aug; 144(2):69-77. PubMed ID: 15322501
[TBL] [Abstract][Full Text] [Related]
14. Small, potent, and selective diaryl phosphonate inhibitors for urokinase-type plasminogen activator with in vivo antimetastatic properties.
Joossens J; Ali OM; El-Sayed I; Surpateanu G; Van der Veken P; Lambeir AM; Setyono-Han B; Foekens JA; Schneider A; Schmalix W; Haemers A; Augustyns K
J Med Chem; 2007 Dec; 50(26):6638-46. PubMed ID: 18052026
[TBL] [Abstract][Full Text] [Related]
15. Urokinase plasminogen activator system: a multifunctional role in tumor progression and metastasis.
Choong PF; Nadesapillai AP
Clin Orthop Relat Res; 2003 Oct; (415 Suppl):S46-58. PubMed ID: 14600592
[TBL] [Abstract][Full Text] [Related]
16. Prognostic significance of growth factors and the urokinase-type plasminogen activator system in pancreatic ductal adenocarcinoma.
Xue A; Scarlett CJ; Jackson CJ; Allen BJ; Smith RC
Pancreas; 2008 Mar; 36(2):160-7. PubMed ID: 18376307
[TBL] [Abstract][Full Text] [Related]
17. [Experimental study of anti-metastasis effect of urokinase amino-terminal fragment gene on human breast cancer cells].
Zhu F; Xing G; He F
Zhonghua Zhong Liu Za Zhi; 2001 Mar; 23(2):115-7. PubMed ID: 11783013
[TBL] [Abstract][Full Text] [Related]
18. The surface of prostate carcinoma DU145 cells mediates the inhibition of urokinase-type plasminogen activator by maspin.
McGowen R; Biliran H; Sager R; Sheng S
Cancer Res; 2000 Sep; 60(17):4771-8. PubMed ID: 10987285
[TBL] [Abstract][Full Text] [Related]
19. Differential inhibition of endothelial cell proliferation and migration by urokinase subdomains: amino-terminal fragment and kringle domain.
Kim KS; Hong YK; Lee Y; Shin JY; Chang SI; Chung SI; Joe Y
Exp Mol Med; 2003 Dec; 35(6):578-85. PubMed ID: 14749538
[TBL] [Abstract][Full Text] [Related]
20. Peptides and small molecules targeting the plasminogen activation system: towards prophylactic anti-metastasis drugs for breast cancer.
Tyndall JD; Kelso MJ; Clingan P; Ranson M
Recent Pat Anticancer Drug Discov; 2008 Jan; 3(1):1-13. PubMed ID: 18289119
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]